Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. [electronic resource]
Producer: 20110816Description: 3037-43 p. digitalISSN:- 1527-7755
- Actuarial Analysis
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- metabolism
- Cetuximab
- Chemotherapy, Adjuvant
- Deoxycytidine -- administration & dosage
- Disease Progression
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Pancreatic Neoplasms -- drug therapy
- Patient Selection
- Radiotherapy, Adjuvant
- Remission Induction
- Research Design
- Smad4 Protein -- metabolism
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.